The feasibility of controlled blood-brain barrier (BBB) disruption in rats was demonstrated with a low-frequency clinical transcranial MRI-guided focused ultrasound device that operates at 230 kHz (ExAblate Neuro, InSightec) combined with microbubbles. Thirty-six targets were sonicated in one hemisphere in each experiment under closed-loop control based on real-time recordings of acoustic emissions. Disruption was confirmed in maps of R1 relaxation following Gadavist administration. After three weekly BBB disruptions covering an entire hemisphere, we always produced BBB disruption with only minor vascular side effects. We also delivered irinotecan chemotherapy across the BBB without apparent neurotoxicity.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords